A major nucleoside-modified trivalent mRNA-LNP vaccine candidate incorporating one entry molecule (i.e., gD2 glycoprotein) and two immune evasion molecules (i.e., gC2 and gE3 glycoproteins) has demonstrated promising results and is now being evaluated in a phase I clinical trial (NCT05432583) [65] in volunteers with recurrent genital herpes, caused by HSV-2. The gene discussed is SLC25A18; the disease is genital herpes.